Shanghai Institute Of Biological Products

This is an early safety study for a new monkeypox vaccine. Researchers will give 120 adults two doses of either the experimental vaccine or a placebo, then monitor them for side effects and measure their immune response. The study aims to find out if the vaccine is safe and if it…

This is an early-stage study to test the safety and body processing of a new vaccine injection, called SIBP-A16, designed to protect against Respiratory Syncytial Virus (RSV). It will involve 140 healthy adults who will receive different doses or a placebo. The main goal is to se…

This study is testing the safety and immune response of a new influenza (flu) vaccine in healthy adults aged 60 and older. It will enroll 120 participants to receive either the new vaccine, an existing vaccine, or a placebo shot. The main goal is to see how safe the new vaccine i…

This study is testing a new shingles vaccine to see if it is safe and if it helps the body build protection against the virus. It will involve about 645 healthy adults aged 40 and older, who will receive two shots. Researchers will compare the new vaccine to an already approved s…

This is an early-stage study to check the safety and find the right dose of a new injectable drug called peguricase, given alongside methotrexate, for people with gout. It is for adults whose gout and high uric acid levels are not controlled by standard oral medications. The main…

This is an early-stage study to test the safety and dosing of a new drug called SIBP-A18 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to up to 156 participants to find the safest maximum dose and …

This is a first-in-human study to test the safety and find the right dose of a new drug called SIBP-A19 for people with advanced solid tumors. It will enroll about 156 adults whose cancer has progressed despite standard treatments. The main goal is to see how much of the drug the…

This is an early-stage study testing a new drug called SIBP-A13 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might help shrin…

This study is testing whether a new drug called SIBP-03, when given with an existing cancer drug (cetuximab), can help control advanced head and neck cancer that has returned or spread. It will involve about 81 adults whose cancer has worsened after previous immunotherapy and che…

This early-stage trial is testing a new drug called SIBP-A17 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to 196 participants to find the safest amount and learn how the body processes the drug. T…

This is a first-in-human study to test the safety and side effects of an experimental drug called SIBP-A10 in people with advanced cancers that have spread. Researchers will give increasing doses to up to 160 participants to find the highest dose that is safe and tolerable. The m…